Fig. 7: DSS-induced colitis is exacerbated by anti-CTLA4, but not LC427.
From: Targeting LRBA triggers CTLA4 degradation and antitumor immunity for cancer immunotherapy
A, B Normalized body weight (A, n = 10 mice) and survival (B, n = 10 mice) curves of mice treated with 3% DSS and receiving LC427 or anti-CTLA4 mAb. C, D Representative H&E staining (C, n = 5 mice) and the histological scores (D, n = 5 mice) of the colon from mice treated with 3% DSS and receiving LC427 or anti-CTLA4 mAb. E Concentrations of CXCL1, TNF-α, IL-6, and IFN-γ in the serum of mice treated with 3% DSS and receiving LC427 or anti-CTLA4 (n = 5 mice). F Quantification of CD11b, CD68, CD163, and Ly6G IHC staining in the colon from mice with 3% DSS and receiving LC427 or anti-CTLA4 (n = 6 mice). Data are mean ± SEM. The n number represents biological replicates (individual mice) obtained from one independent experiment. Statistical significance was assessed using Kaplan-Meier survival analyses and one-way ANOVA. Source data are provided as a Source Data file.
